EVIDENCE OF CLINICAL EFFICACY
ACETYL TETRAPEPTIDE-40
CLINICALLY PROVEN FOR:
Promotes the lipid accumulation in adypocytes
DESCRIPTION: The dermal connective tissue may be damaged as the
proteolytic degradation of the extracellular matrix
Tetrapeptide that decreases the appearance (ECM), mainly of collagen, is increased due to Matrix
of facial redness and telangiectasia caused by Metalloproteinases (MMPs) activation. Therefore, red
an exaggerated inflammatory response. Acetyl areas become more visible as capillaries are fragile
tetrapeptide-40 reduces the release of interleukins and permeable, and blood vessels can easily dilate
(IL-6 and IL-8) induced by 37-amino-acid peptide (LL- due to inflammation. Acetyl tetrapeptide-40 helps
37), cathelicidin overexpressed in skin disorders with to decrease facial redness and other skin disorders
erythema. caused by LL-37 activation and subsequent release of
ILs. It also provides a photoprotective effect lowering
Acetyl tetrapeptide-40 fights the undesired effects cell damage and skin inflammation negative effects.
caused by inflammation such as skin redness and
dilated blood vessels, tissue degradation as well as IN VITRO:
post-inflammatory hyperpigmentation and dull skin.
1-INHIBITION OF LL-37-INDUCED IL RELEASE
Acetyl tetrapeptide-40 is incorporated into
formulations designed to reduce facial redness The inhibition of the activity of LL-37 was measured
and telangiectasia, improving even skin tone, while by the release of the key pro-inflammatory cytokines
providing additional firming and photoprotective IL-6 and IL-8 in human primary keratinocytes treated
effects. with LL-37 alone or with Acetyl tetrapeptide-40.
Quantification was performed by ELISA.
SCIENCE: Acetyl tetrapeptide-40 lowers LL-37-mediated
IL-6 and IL-8 release IL-6 levels decreased
In the natural response of the immune system to by 24.2% and IL-8, by 22.8% with Acetyl
potential harmful agents and conditions, kallikreins tetrapeptide-40 at 0.5mg/ml.
and antimicrobial compounds like cathelicidins
have an important role. They induce the release of 2- ANTI-COLLAGENASE ASSAY
interleukines (IL), which are among the increased
molecules in facial skin redness and vascular The anti-collagenase effect of Acetyl tetrapeptide-40
alterations. In skin disorders with erythema and was evaluated by measuring the fluorescence of
dilated blood vessels, like rosacea, LL-37 expression the fluorescein conjugate (gelatine). Fluorescence
is found to be abnormally high, it is locally activated intensity is proportional to proteolytic activity.
and a cascade of inflammatory reactions leads to an
increase of pro-inflammatory metabolites, IL-6 and Connective tissue degradation is reduced by
IL-8 among others. Acetyl tetrapeptide-40. Acetyl tetrapeptide-40
demonstrated a statistically significant
inhibitory effect on collagenase activity.
HB aesthetics
EVIDENCE OF CLINICAL EFFICACY
ACETYL TETRAPEPTIDE-40
IN VIVO: Erythema, redness and extent intensity are
reduced with Acetyl tetrapeptide-40.
1- SKIN REDNESS IMPROVEMENT
Skin roughness diminished as well, by 7.5% at
A group of 20 volunteers (aged between 25 and 65) the end of the treatment.
with healthy skin but mild rosacea applied a cream
containing 2% Acetyl tetrapeptide-40 solution twice - Instrumental evaluation
a day for 28 days.
VISIA analysis was performed in 5 of the volunteers
- Dermatological evaluation at the end of the treatment (4 weeks). Feature counts
A trained specialist evaluated erythema, skin redness are the number of red areas and absolute scores are
and extent intensity as well as skin roughness using the size and intensity of the red areas.
a scale from no intensity to maximum intensity, after
1 and 4 weeks.
Acetyl tetrapeptide-40 decreases facial redness,
reducing the number of red areas as well as
their size and intensity.
HB aesthetics
